JP2023523323A5 - - Google Patents

Info

Publication number
JP2023523323A5
JP2023523323A5 JP2022565600A JP2022565600A JP2023523323A5 JP 2023523323 A5 JP2023523323 A5 JP 2023523323A5 JP 2022565600 A JP2022565600 A JP 2022565600A JP 2022565600 A JP2022565600 A JP 2022565600A JP 2023523323 A5 JP2023523323 A5 JP 2023523323A5
Authority
JP
Japan
Prior art keywords
composition
administered
mek inhibitor
kras
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523323A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029435 external-priority patent/WO2021222278A1/en
Publication of JP2023523323A publication Critical patent/JP2023523323A/ja
Publication of JP2023523323A5 publication Critical patent/JP2023523323A5/ja
Pending legal-status Critical Current

Links

JP2022565600A 2020-04-27 2021-04-27 異常な細胞成長を処置する方法 Pending JP2023523323A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063015883P 2020-04-27 2020-04-27
US63/015,883 2020-04-27
PCT/US2021/029435 WO2021222278A1 (en) 2020-04-27 2021-04-27 Methods of treating abnormal cell growth

Publications (2)

Publication Number Publication Date
JP2023523323A JP2023523323A (ja) 2023-06-02
JP2023523323A5 true JP2023523323A5 (enExample) 2024-05-10

Family

ID=78332185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565600A Pending JP2023523323A (ja) 2020-04-27 2021-04-27 異常な細胞成長を処置する方法

Country Status (11)

Country Link
US (1) US20230201198A1 (enExample)
EP (1) EP4142882A4 (enExample)
JP (1) JP2023523323A (enExample)
KR (1) KR20230011277A (enExample)
CN (1) CN115916346A (enExample)
AU (1) AU2021263742A1 (enExample)
BR (1) BR112022021657A2 (enExample)
CA (1) CA3175481A1 (enExample)
IL (1) IL297650A (enExample)
MX (1) MX2022013430A (enExample)
WO (1) WO2021222278A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021206684B2 (en) 2020-01-10 2024-01-18 Immuneering Corporation MEK inhibitors and therapeutic uses thereof
WO2023138630A1 (zh) * 2022-01-21 2023-07-27 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2023147297A2 (en) * 2022-01-25 2023-08-03 Verastem, Inc. Combination therapy for treating abnormal cell growth
CA3252402A1 (en) * 2022-02-28 2025-07-07 Wigen Biomedicine Technology (shanghai) Co., Ltd. COMPOUND USED AS A FAK INHIBITOR AND ITS USE
AU2023250314A1 (en) * 2022-04-08 2024-10-03 Mirati Therapeutics, Inc. Combination therapies comprising a sos1 inhibitor and a mek inhibitor
EP4531846A1 (en) * 2022-06-03 2025-04-09 Verastem, Inc. Combination therapy for treating abnormal cell growth
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
TW202517624A (zh) * 2023-07-03 2025-05-01 美商醫療免疫工程公司 Mek免疫腫瘤抑制劑醫藥組合物
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法
WO2025261499A1 (zh) * 2024-06-20 2025-12-26 上海科州药物股份有限公司 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120214828A1 (en) * 2009-08-24 2012-08-23 Georgia Hatzivassiliou Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
AU2016258192B2 (en) * 2015-05-06 2021-07-29 Leidos Biomedical Research, Inc. K-Ras modulators
KR102811888B1 (ko) * 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
MX2022006366A (es) * 2019-11-27 2022-06-22 Turning Point Therapeutics Inc Terapia de combinacion que implica compuestos de diarilo macrociclico.

Similar Documents

Publication Publication Date Title
JP2023523323A5 (enExample)
JP2019532051A5 (enExample)
Aoyama et al. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer
Ducreux et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)
JP2022519375A5 (enExample)
Fischer et al. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
JP2024527109A5 (enExample)
JP2018526376A5 (enExample)
Ji et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis
Kodera Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan
Kobayashi et al. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
Gruber et al. Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model
Tanaka et al. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
JP2024528705A5 (enExample)
Liao et al. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
Ilson Immunotherapy in esophagogastric cancer
Deng et al. Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
El Din Sunitinib 4/2 Versus 2/1 schedule for patients with metastatic renal cell carcinoma: tertiary care hospital experience
Zhang et al. Successful treatment of ovarian cancer with apatinib combined with chemotherapy: a case report
Toyoda et al. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)
Leng et al. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting
Hampton Cancer Drug Trials Show Modest Benefit
Lim et al. Gemcitabine and erlotinib with or without oxaliplatin in previously untreated advanced pancreatic cancer: A randomized phase II trial
Yang et al. Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer
Yanagimoto et al. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)